ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Candidate UTI vaccine low dose formulation 1

Also written as “Candidate UTI vaccine low dose formulation 2”, “Candidate UTI vaccine medium dose formulation 1” and “Candidate UTI vaccine medium dose formulation 2”.

Its studies are mostly in Urinary Tract Infections, led by GlaxoSmithKline.

Furthest: phase 2, since Nov 20, 20241 company-led study, 1 open or runningNext primary completion: May 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 2since Nov 20, 2024Nov 20, 2024May 31, 2027phase 2 · NCT06702449

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2024First study: phase 2 study in Urinary Tract InfectionsFirst studyNCT06702449 · 448 planned · United States, South Africa

Ahead

  1. May 31, 2027Primary completion: phase 2 study in Urinary Tract InfectionsNCT06702449

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Candidate UTI vaccine low dose formulation 1”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06702449Urinary Tract Infections · United States, South Africa2RecruitingMay 31, 2027448

How it is read

Names in the registry

  • “Candidate UTI vaccine low dose formulation 1”, 1 entry
  • “Candidate UTI vaccine low dose formulation 2”, 1 entry
  • “Candidate UTI vaccine medium dose formulation 1”, 1 entry
  • “Candidate UTI vaccine medium dose formulation 2”, 1 entry
  • “Candidate UTI vaccine high dose formulation 1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.